Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Data Reaffirms Test's Ability to… >
Data Reaffirms Test's Ability to Identify Benign Thyroid Nodules

Published: October 24, 2013.
By University of Colorado Denver
http://www.ucdenver.edu

Aurora, CO (Oct. 23, 2013) The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment. These indeterminate nodules are being evaluated with a new molecular diagnostic test that measures the expression levels of 142 genes. This test is able to identify which initially indeterminate nodules are highly likely to be benign, and thus allows patients to avoid unnecessary diagnostic surgery.

This multi-site study co-led by Bryan R. Haugen, MD, professor of medicine and pathology at the University of Colorado School of Medicine provides the first long-term look at how these patients fared, and its findings reaffirm the performance of the Afirma Gene Expression Classifier (GEC). Haugen said "Each year, tens of thousands of patients with thyroid nodules have surgery to remove all or part of their thyroids. This is due to fine needle aspiration (FNA) cell test results that are indeterminate or inconclusive yet raise suspicions for thyroid cancer. Often times, most of these nodules prove to be benign. Our findings suggest that when the GEC identifies an otherwise indeterminate thyroid nodule as benign – which it does about 50% of the time – it is comparable in accuracy to a benign diagnosis by cytopathology, This fact and the degree to which physicians and patients in the study opted against surgery when the molecular test result was benign underscore the test's potential to drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment."

Researchers analyzed all patients who had received Afirma GEC testing following indeterminate FNA biopsy results at five academic medical centers between 2010 and 2013. The GEC identified 174 of 339 (51%) indeterminate nodules as benign and, among these, 71 had documented clinical follow-up for an average of 9 months. Of these, only one nodule proved cancerous, demonstrating a very high negative predictive value (NPV) for the GEC. This finding is consistent with results from an earlier prospective, multicenter clinical study. Additionally, in the new study only 6% of patients with nodules identified as benign by the GEC test underwent surgery. This is a substantial reduction compared to traditional surgical rates for patients with cytologically indeterminate thyroid nodules.

Thyroid nodules are common, but only approximately 5-15% prove malignant. Most nodules are evaluated using FNA, with approximately 525,000 thyroid nodule FNAs performed in the U.S. in 2011 to rule out cancer. In most cases, the results are benign, yet in approximately 15-30% of cases the results are indeterminate – not clearly benign or malignant. Because of the risk of thyroid cancer, most of these patients have historically been recommended for surgery to remove all or part of the thyroid to obtain a final diagnosis. However, such indeterminate nodules prove ultimately benign in 70-80% of cases. For these patients, the surgery was not needed and they were unnecessarily exposed to the cost, risk and morbidity of this intervention. Additionally, most patients subsequently require lifelong thyroid hormone therapy.

The study is published online in the Journal of Clinical Endocrinology & Metabolism and its findings were presented recently at the 83rd Annual Meeting of the American Thyroid Association, held in Puerto Rico.

The long-term findings built on the previous study which demonstrates the Afirma Gene Expression Classifier's accuracy was published in the New England Journal of Medicine.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Patients 
8/26/13 
Thyroid Ultrasound Imaging May Be Useful to Reduce Biopsies in Patients with Low Risk of Cancer
By The JAMA Network Journals
Thyroid ultrasound imaging could be used to identify patients who have a low risk of cancer for whom biopsy could be postponed, according to a study by Rebecca Smith-Bindman, …
Test 
6/17/13 
'Gene Signature' Test Diagnoses Benign Thyroid Growths
By The Endocrine Society
A new genetic test accurately and consistently diagnoses benign growths, or nodules, on the thyroid gland, according to a study from Chile. The results will be presented Saturday at …
Center 
7/25/14 
Test Increases Odds of Correct Surgery for Thyroid Cancer Patients
By University of Pittsburgh Schools of the Health Sciences
PITTSBURGH -- The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and …
Treatment 
8/27/13 
Zealous Imaging Fuelling Unnecessary And Harmful Treatment of Low Risk Thyroid Cancers
By BMJ-British Medical Journal
New technologies such as ultrasound, CT and MRI scanning can detect thyroid nodules as small as 2mm – many of these small nodules are papillary thyroid cancers. In …
Patients 
8/26/13 
Thyroid Cancer Biopsy Guidelines Should Be Simplified, Researchers Say
By University of California - San Francisco
A team led by UC San Francisco researchers has called for simplified guidelines on when to biopsy thyroid nodules for cancer, which they say would result in fewer unnecessary …
Thyroid 
11/7/12 
First Comprehensive Guidelines for Managing Anaplastic Thyroid Cancer Published in Thyroid Journal
By Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, November 7, 2012—Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, …
Cancer 
2/24/14 
★★★★ 
Secondary Thyroid Cancer More Deadly Than Primary Malignancy in Young Individuals
By Wiley
A new analysis has found that adolescents and young adults who develop thyroid cancer as a secondary cancer have a significantly greater risk of dying than those with primary …
Cancer 
9/10/14 
Thyroid Cancer Rates in Pennsylvania Rising Faster Than Rest of Country
By Penn State
Incidence of thyroid cancer is rising faster in Pennsylvania than in the rest of the United States, according to Penn State College of Medicine researchers. …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition